Royalty Pharma plc (RPRX) EBITDA
Royalty Pharma plc (RPRX) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income $133.12M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income $563.04M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income $427.16M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income $209.80M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | (m) | $133.12M | (m) | (m) | (m) | (m) | $728.46M* | (m) | $97.85M | (m) | $0.00 |
|---|
| 2026-03-31 | Reported | (m) | $563.04M | (m) | (m) | (m) | (m) | $718.23M | (m) | $39.79M | (m) | $0.00 |
|---|
| 2025-09-30 | Reported | (m) | $427.16M | (m) | (m) | (m) | (m) | $702.62M* | (m) | $50.50M | (m) | $0.00 |
|---|
| 2025-06-30 | Reported | (m) | $209.80M | (m) | (m) | (m) | (m) | $363.98M* | (m) | $300.50M | (m) | $0.00 |
|---|
| 2025-03-31 | Reported | (m) | $534.18M | (m) | (m) | (m) | (m) | $596.08M | (m) | $50.50M | (m) | $0.00 |
|---|
| 2024-09-30 | Reported | (m) | $735.07M | (m) | (m) | (m) | (m) | $703.61M* | (m) | $500.00K | (m) | $0.00 |
|---|
| 2024-06-30 | Reported | (m) | $269.63M | (m) | (m) | (m) | (m) | $658.21M* | (m) | $500.00K | (m) | $0.00 |
|---|
| 2024-03-31 | Reported | (m) | -$73.77M | (m) | (m) | (m) | (m) | $664.64M | (m) | $500.00K | (m) | $0.00 |
|---|
| 2023-09-30 | Reported | (m) | $151.44M | (m) | (m) | (m) | (m) | $573.52M* | (m) | $50.50M | (m) | $0.00 |
|---|
| 2023-06-30 | Reported | (m) | $248.84M | (m) | (m) | (m) | (m) | $607.82M* | (m) | $500.00K | (m) | $0.00 |
|---|
| 2023-03-31 | Reported | (m) | $478.97M | (m) | (m) | (m) | (m) | $1.03B | (m) | $500.00K | (m) | $0.00 |
|---|
| 2022-09-30 | Reported | (m) | $192.21M | (m) | (m) | (m) | (m) | $538.83M* | (m) | $25.50M | (m) | $0.00 |
|---|
| 2022-06-30 | Reported | (m) | $377.79M | (m) | (m) | (m) | (m) | $574.95M* | (m) | $606.00K | (m) | $0.00 |
|---|
| 2022-03-31 | Reported | (m) | $219.72M | (m) | (m) | (m) | (m) | $460.27M | (m) | $100.50M | (m) | $0.00 |
|---|
| 2021-09-30 | Reported | (m) | $303.05M | (m) | (m) | (m) | (m) | $469.76M* | (m) | $90.50M | (m) | $0.00 |
|---|
| 2021-06-30 | Reported | (m) | $744.95M | (m) | (m) | (m) | (m) | $531.72M* | (m) | $3.12M | (m) | $0.00 |
|---|
| 2021-03-31 | Reported | (m) | $229.30M | (m) | (m) | (m) | (m) | $526.10M | (m) | $2.64M | (m) | $0.00 |
|---|
| 2020-09-30 | Reported | (m) | $510.57M | (m) | (m) | (m) | (m) | $508.85M* | (m) | $5.10M | (m) | $0.00 |
|---|
| 2020-06-30 | Reported | (m) | $409.35M | (m) | (m) | (m) | (m) | $489.00M* | (m) | $5.78M | (m) | $0.00 |
|---|
| 2020-03-31 | Reported | (m) | $361.43M | (m) | (m) | (m) | (m) | $471.10M | (m) | $7.64M | (m) | $0.00 |
|---|
| 2019-09-30 | Reported | (m) | $532.50M | (m) | (m) | (m) | (m) | $419.03M* | (m) | $22.72M | (m) | $0.00 |
|---|
| 2019-06-30 | Reported | (m) | $327.86M | (m) | (m) | (m) | (m) | (m) | (m) | $21.46M | (m) | $0.00 |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | (m) | $1.56B | (m) | (m) | (m) | (m) | $2.49B | (m) | $452.00M | (m) | $0.00 |
|---|
| 2024-12-31 | Reported | (m) | $1.29B | (m) | (m) | (m) | (m) | $2.77B | (m) | $2.00M | (m) | $0.00 |
|---|
| 2023-12-31 | Reported | (m) | $1.49B | (m) | (m) | (m) | (m) | $2.99B | (m) | $52.00M | (m) | $0.00 |
|---|
| 2022-12-31 | Reported | (m) | $307.06M | (m) | (m) | (m) | (m) | $2.14B | (m) | $177.11M | (m) | $0.00 |
|---|
| 2021-12-31 | Reported | (m) | $1.43B | (m) | (m) | (m) | (m) | $2.02B | (m) | $200.08M | (m) | $0.00 |
|---|
| 2020-12-31 | Reported | (m) | $1.60B | (m) | (m) | (m) | (m) | $2.03B | (m) | $26.29M | (m) | $0.00 |
|---|
| 2019-12-31 | Reported | (m) | $2.62B | (m) | (m) | (m) | (m) | $1.67B | (m) | $83.04M | (m) | $0.00 |
|---|
| 2018-12-31 | Reported | (m) | $1.36B | (m) | (m) | (m) | (m) | $1.62B | (m) | $392.61M | (m) | $0.00 |
|---|